DECEMBER 202419LIFE SCIENCES REVIEWleaves the door open for innovative design possibilities for future advancements, such as multiplexing.Beyond these competencies, Cranebio addresses the challenge of false positives caused by contamination; a critical concern for at-home testing. Its reagents work through simple mixing while its strategies to prevent dispersion of amplification product ensure consistent accuracy and reliability. It also plans to develop a device that can simultaneously handle 8­16 reactions , to accommodate professionals looking for cost-effective bulk testing. While this is a departure from its device-less approach, it's a practical solution for a specific need, further demonstrating Cranebio's commitment to making genetic testing affordable and accessible.A Whole World of Applications AwaitsCranebio is advancing healthcare innovation with novel applications such as a wearable testing kit for women. This kit integrates a lateral flow immunoassay into a panty liner, providing a convenient tool for health monitoring. Its recent ovulation prediction kit, launched in Japan, further highlights the company's commitment to groundbreaking solutions. Saito also wants to focus on oncology, particularly early cancer detection and disease management, with HPV as an initial target. In oral health, a recent partnership has paved the way for developing a periodontitis management kit, showcasing Cranebio's ability to tackle complex health challenges with versatile solutions. It is now exploring opportunities for growth in the U.S. The technology's applications extend far beyond medical diagnostics. It offers transformative testing solutions for food and water safety inspections, delivering immediate insights that enhance safety protocols and prevent potential outbreaks. This contrasts with traditional methods, which rely on time-consuming cultivation techniques that can take days to produce results.In addition, Dozyme-based testing has significant potential in livestock diagnostics, including applications for cows, pigs and chickens. For instance, avian influenza outbreaks often force poultry farmers to cull entire flocks as a precautionary measure. Cranebio's highly sensitive testing approach could help identify non-infected chickens for isolation, reducing losses and improving disease management. This capability demonstrates how the technology can address critical challenges across diverse industries.At the Forefront of Next-Generation DiagnosticsThe global PCR testing market, valued at around $9 billion, presents a significant opportunity. Offering a cost-effective and user-friendly solution that overcomes the limitations of traditional testing techniques, Cranebio stands at the forefront of next-generation diagnostics. Its scalable and adaptable technology is designed to meet both current and future healthcare needs, ensuring timely and accurate treatments that enhance patient care and outcomes. With a mission to revolutionize diagnostics, the company's versatile platform enables rapid test development across diverse applications. Supported by strong distribution partners, Cranebio is well-positioned to drive growth in healthcare, food safety and environmental monitoring, improving quality of life on a global scale.By making advanced diagnostics accessible to all, Cranebio is gaining a competitive edge while redefining the future of diagnostic testing. Keita Saito,Chief Technology OfficerTOP 10GENOMICSSOLUTIONS PROVIDERS IN APAC 2024
< Page 9 | Page 11 >